HomeClinical TopicsFDA approves expanded use of Isentress in children and adolescents

FDA approves expanded use of Isentress in children and adolescents

The U.S. Food and Drug Administration has approved Isentress (raltegravir) for use with other antiretroviral drugs for the treatment of HIV-1 infection for children and adolescents ages 2 to 18. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

Women suffering from a migraine

Quiz: Migraines and Hormones

Women are 2 to 3 times more likely than men to have migraines.  Decades ago, these were attributed to women’s inability to cope with...